Trial · NCT03434041
Adverse events96
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 96
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vision Blurred | Eye disorders | Double-blind: Intranasal Esketamine+ Oral Antidepressant (AD) | 23 | 126 | |
| other | Vision Blurred | Eye disorders | Double-blind: Oral AD + Intranasal Placebo | 1 | 126 | |
| other | Vision Blurred | Eye disorders | Follow-up: Intranasal Esketamine+ Oral AD | 0 | 106 | |
| other | Vision Blurred | Eye disorders | Follow-up: Oral AD + Intranasal Placebo | 0 | 103 | |
| other | Constipation | Gastrointestinal disorders | Double-blind: Intranasal Esketamine+ Oral Antidepressant (AD) | 3 | 126 | |
| other | Constipation | Gastrointestinal disorders | Double-blind: Oral AD + Intranasal Placebo | 2 | 126 | |
| other | Constipation | Gastrointestinal disorders | Follow-up: Intranasal Esketamine+ Oral AD | 1 | 106 | |
| other | Constipation | Gastrointestinal disorders | Follow-up: Oral AD + Intranasal Placebo | 6 | 103 | |
| other | Hypoaesthesia Oral | Gastrointestinal disorders | Double-blind: Intranasal Esketamine+ Oral Antidepressant (AD) | 10 | 126 | |
| other | Hypoaesthesia Oral | Gastrointestinal disorders | Double-blind: Oral AD + Intranasal Placebo | 1 | 126 | |
| other | Hypoaesthesia Oral | Gastrointestinal disorders | Follow-up: Intranasal Esketamine+ Oral AD | 0 | 106 | |
| other | Hypoaesthesia Oral | Gastrointestinal disorders | Follow-up: Oral AD + Intranasal Placebo | 0 | 103 | |
| other | Nausea | Gastrointestinal disorders | Double-blind: Intranasal Esketamine+ Oral Antidepressant (AD) | 53 | 126 | |
| other | Nausea | Gastrointestinal disorders | Double-blind: Oral AD + Intranasal Placebo | 17 | 126 | |
| other | Nausea | Gastrointestinal disorders | Follow-up: Intranasal Esketamine+ Oral AD | 0 | 106 | |
| other | Nausea | Gastrointestinal disorders | Follow-up: Oral AD + Intranasal Placebo | 3 | 103 | |
| other | Vomiting | Gastrointestinal disorders | Double-blind: Intranasal Esketamine+ Oral Antidepressant (AD) | 23 | 126 | |
| other | Vomiting | Gastrointestinal disorders | Double-blind: Oral AD + Intranasal Placebo | 2 | 126 | |
| other | Vomiting | Gastrointestinal disorders | Follow-up: Intranasal Esketamine+ Oral AD | 0 | 106 | |
| other | Vomiting | Gastrointestinal disorders | Follow-up: Oral AD + Intranasal Placebo | 2 | 103 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03434041/events